

Cancer Australia

Entity resources and planned performance

Cancer Australia

Section 1: Entity overview and resources	264
1.1 Strategic direction statement.....	264
1.2 Entity resource statement.....	265
1.3 Budget measures.....	267
Section 2: Outcomes and planned performance	268
2.1 Budgeted expenses and performance for Outcome 1.....	268
Section 3: Budgeted financial statements	276
3.1 Budgeted financial statements.....	276
3.2. Budgeted financial statements tables.....	277

Cancer Australia

Section 1: Entity overview and resources

1.1 Strategic direction statement¹

As the Australian Government’s national cancer control agency, Cancer Australia aims to reduce the impact of cancer, address disparities, and improve outcomes for people affected by cancer. The Australian Government, through Cancer Australia:

- provides national leadership in cancer control
- facilitates evidence-informed approaches with a range of healthcare providers and groups across the continuum of care
- leads the development of sustainable and effective models of cancer care
- oversees a dedicated budget for cancer research, supports clinical trial capacity and strengthens national data capacity
- provides advice on appropriate cancer care.

To achieve its aims in 2025–26, Cancer Australia will use an evidence-based approach and collaboratively engage with stakeholders to:

- lead the implementation of the Australian Cancer Plan to improve outcomes for all Australians affected by cancer
- partner with First Nations leaders to co-design and deliver improved cancer care for First Nations peoples
- translate evidence to inform best practice cancer care
- oversee a dedicated budget for research into cancer
- support industry-independent cancer clinical trials groups
- drive efforts to strengthen national data capacity
- provide evidence-based cancer information to cancer consumers, health professionals and the community.

The role and functions of Cancer Australia are set out in the *Cancer Australia Act 2006*. Cancer Australia is subject to the *Public Service Act 1999* and the *Auditor-General Act 1997*, and is a non-corporate Commonwealth entity under the *Public Governance, Performance and Accountability Act 2013*.

¹ For more information about the strategic direction of Cancer Australia, refer to the current Corporate Plan, available at: www.canceraustralia.gov.au/sites/default/files/2024-09/Cancer-Australia-Corporate-Plan-2024-25.pdf

1.2 Entity resource statement

Table 1.1 shows the total resourcing from all sources available to the entity for its operations and to deliver programs and services on behalf of the Government.

The table summarises how resources will be applied by outcome (government strategic policy objectives) and by administered (on behalf of the Government or the public) and departmental (for the entity's operations) classification.

For more detailed information on special accounts and special appropriations, please refer to the *Budget Paper No. 4 – Agency Resourcing*.

Information in this table is presented on a resourcing (that is, appropriations/cash available) basis, whilst the 'Budgeted expenses by Outcome 1' tables in Section 2 and the financial statements in Section 3 are presented on an accrual basis. Amounts presented below are consistent with amounts presented in the Appropriation Bills themselves.

Table 1.1: Cancer Australia resource statement – Budget estimates for 2025–26 as at Budget March 2025

	2024–25 Estimated actual \$'000	2025–26 Estimate \$'000
DEPARTMENTAL		
Prior year appropriation available	3,111	3,103
Annual appropriations		
Ordinary annual services ^(a)		
Departmental appropriation	14,109	13,371
s74 retained revenue receipts ^(b)	3,083	2,512
Departmental Capital Budget ^(c)	85	85
Other services ^(d)		
Equity injection	-	-
Total departmental annual appropriations	17,277	15,968
Total departmental resourcing	20,388	19,071
ADMINISTERED		
Prior year appropriation available	1,051	1,051
Annual appropriations		
Ordinary annual services ^(a)		
Outcome 1	34,362	33,199
Other services ^(d)		
Administered assets and liabilities	-	-
Total administered annual appropriations	34,362	33,199
Total administered resourcing	35,413	34,250
Total resourcing for Cancer Australia	55,801	53,321
	2024–25	2025–26
Average staffing level (number)	79	75

All figures are GST exclusive.

^(a) Appropriation Bill (No. 1) 2025–2026 and Supply Bill (No. 1) 2025–2026.

^(b) Estimated retained revenue receipts under section 74 of the *Public Governance, Performance and Accountability Act 2013* (PGPA Act).

^(c) Departmental Capital Budgets are not separately identified in Appropriation Bill (No. 1) and form part of ordinary annual services items. Please refer to Table 3.5 within this chapter for further details. For accounting purposes, this amount has been designated as a 'contribution by owner'.

^(d) Appropriation Bill (No. 2) 2025–2026 and Supply Bill (No. 2) 2025–2026.

1.3 Budget measures

Budget measures in Part 1 relating to Cancer Australia are detailed in the Budget Paper No. 2 and are summarised below.

Table 1.2: Cancer Australia 2025–26 Budget measures

Part 1: Measures announced since the 2024–25 Mid-Year Economic and Fiscal Outlook (MYEFO)

Program	2024–25 \$'000	2025–26 \$'000	2026–27 \$'000	2027–28 \$'000	2028–29 \$'000
Savings from External Labour - further extension ^(a)					
Cancer Australia	1.1				
Departmental payments	-	-	-	-	(37)
Total payments	-	-	-	-	(37)

Prepared on a Government Financial Statistics (Underlying Cash) basis. Figures displayed as a negative (-) represent a decrease in funds and a positive (+) represent an increase in funds.

^(a) Cancer Australia is not the lead entity for this measure. Cancer Australia impacts only are shown in this table.

Section 2: Outcomes and planned performance

Government outcomes are the intended results, impacts or consequences of actions by the Government on the Australian community. Commonwealth programs are the primary vehicle by which government entities achieve the intended results of their outcome statements. Entities are required to identify the programs which contribute to government outcomes over the Budget and forward years.

Each outcome is described below together with its related programs. The following provides detailed information on expenses for each outcome and program, further broken down by funding source.

Note:

Performance reporting requirements in the Portfolio Budget Statements are part of the Commonwealth performance framework established by the *Public Governance, Performance and Accountability Act 2013*. It is anticipated that the performance measure described in Portfolio Budget Statements will be read with broader information provided in an entity's corporate plans and annual performance statements – included in Annual Reports – to provide a complete picture of an entity's planned and actual performance.

The most recent Corporate Plan for Cancer Australia can be found at:
www.canceraustralia.gov.au/sites/default/files/2024-09/Cancer-Australia-Corporate-Plan-2024-25.pdf

The most recent Annual Performance Statements can be found at:
www.canceraustralia.gov.au/about-us/accountability-and-reporting/annual-reports

2.1 Budgeted expenses and performance for Outcome 1

Outcome 1

Minimised impacts of cancer, including through national leadership in cancer control with targeted research and clinical trials; evidence informed clinical practice; strengthened national data capacity; community and consumer information and support.

Program contributing to Outcome 1

Program 1.1: Improved Cancer Control

Linked programs

Other Commonwealth entities that contribute to Outcome 1
Department of Health and Aged Care
Program 1.1: Health Research, Coordination and Access
The Department of Health and Aged Care has responsibility for health and medical research through the Medical Research Future Fund, which will support the sustainability of the health system into the future and drive further medical innovation.
Program 1.5: Preventive Health and Chronic Disease Support
The Department of Health and Aged Care has policy responsibility for improving the detection, treatment and survival outcomes for people with cancer. This includes oversight of cancer screening programs, such as the National Bowel Cancer Screening Program, the BreastScreen Australia Program and the National Cervical Screening Program.

Budgeted expenses for Outcome 1

This table shows how much the entity intends to spend (on an accrual basis) on achieving the outcome, broken down by program, as well as by Administered and Departmental funding sources.

Table 2.1.1: Budgeted expenses for Outcome 1

	2024–25 Estimated actual \$'000	2025–26 Budget \$'000	2026–27 Forward estimate \$'000	2027–28 Forward estimate \$'000	2028–29 Forward estimate \$'000
Program 1.1: Improved Cancer Control					
Administered expenses					
Ordinary annual services ^(a)	34,362	33,199	33,388	22,608	22,324
Departmental expenses					
Departmental appropriation ^(b)	17,192	15,883	15,809	12,422	12,546
Expenses not requiring appropriation in the Budget year ^(c)	145	149	125	283	329
Operating deficit (surplus)	-	-	-	-	-
Total for Program 1.1	51,699	49,231	49,322	35,313	35,199
Total expenses for Outcome 1	51,699	49,231	49,322	35,313	35,199
	2024–25	2025–26			
Average staffing level (number)	79	75			

^(a) Appropriation Bill (No. 1) 2025–2026 and Supply Bill (No. 1) 2025–2026.

^(b) Departmental appropriation combines 'Ordinary annual services Appropriation Bill (No. 1)', 'Supply Bill (No. 1)' and 'Revenue from independent sources (s74)'.
(c) Expenses not requiring appropriation in the Budget year are made up of depreciation expense, amortisation expense, makegood expenses and audit fees, interest on RoU (Right-of-Use asset) and credit applied to rental supplier expenses (rental payments).

Performance measures for Outcome 1

Table 2.1.2 details the performance measures for each program associated with Outcome 1. It is used by entities to describe the results they plan to achieve and the related key activities, as detailed in the current corporate plan, the context in which these activities are delivered, and how the performance of these activities will be measured. Where relevant, details of the 2025–26 Budget measures that have created new programs or materially changed existing programs are provided.

Table 2.1.2: Performance measures for Outcome 1

Outcome 1	
Minimised impacts of cancer, including through national leadership in cancer control with targeted research and clinical trials; evidence informed clinical practice; strengthened national data capacity; community and consumer information and support.	
Program 1.1: Improved Cancer Control	
Provide national leadership in cancer control across the care continuum to reduce the impact of cancer, address disparities, and improve outcomes for people affected by cancer through the development and promotion of evidence-based practice, funding cancer research, and providing consumers and health professionals with cancer information and resources.	
Key Activities	<ul style="list-style-type: none"> • Provide national leadership in cancer control. • Develop and promote evidence-based best practice cancer care. • Fund cancer research and drive efforts to strengthen national data capacity in consultation with relevant agencies. • Provide consumer and health professional cancer information and resources.

Program 1.1: Improved Cancer Control		
Year	Performance Measure	Expected Performance Results
Current Year 2024–25	Lead the implementation of the Australian Cancer Plan (the Plan), which sets out national priorities and action areas over the next 10 years to improve outcomes for all Australians affected by cancer.	Engage with the cancer sector to communicate and promote uptake of the Plan's objectives, goals and ambitions, including establishing Partnership Agreements with stakeholders. Progress on foundational implementation projects in support of the Plan's 2-year goals: <ul style="list-style-type: none"> - Australian Comprehensive Cancer Network (ACCN) Framework completed and published. Network launched and continues to grow. - National Optimal Care Pathways Framework completed and published. Implementation commenced. - National Cancer Data Framework drafted, and public consultation completed. - National Framework for Genomics in Cancer Control drafted, and public consultation completed. Framework finalised for publication. Achieved
Year	Performance Measure	Planned Performance Results
Budget Year 2025–26	Evaluation of the sector's progress towards the Australian Cancer Plan's 2-year actions. Progress activities to achieve priority 5-year actions in the Plan (2026–28).	Undertake evaluation of the sector's progress [including the Commonwealth, States and Territories and cancer control stakeholders] of delivering on the Plan's 2-year actions (2025–26). Review and progress activities to achieve priority 5-year actions in the Plan. Complete and Publish the National Cancer Data Framework.
Forward Estimates 2026–29	Monitoring and evaluation of the sector's progress towards the Australian Cancer Plan's 5-year actions.	Assessment of potential gaps and required responses in implementation of the Plan as needed. Evaluate progress towards 5-year actions and update as needed. Define to deliver 10-year ambitions.

Program 1.1: Improved Cancer Control		
Year	Performance Measure	Expected Performance Results
Current Year 2024–25	Work in partnership with the Department of Health and Aged Care (lead) and the National Aboriginal Community Controlled Health Organisation (NACCHO) to co-design and implement the National Lung Cancer Screening Program (NLCSP) by July 2025.	Collaboratively engage with key stakeholders to develop and deliver Program Guidelines, information and education resources and other clinical materials to support the implementation of the NLCSP. On track
Year	Performance Measure	Planned Performance Results
Budget Year 2025–26	Support the Department of Health and Aged Care in ongoing implementation activities for the NLCSP.	Commence program-specific research activities.
Forward Estimates 2026–29	As per 2025–26.	Continued investment in program-specific research activities.

Program 1.1: Improved Cancer Control		
Year	Performance Measure	Expected Performance Results
Current Year 2024–25	Lead delivery of 5 early implementation National Pancreatic Cancer Roadmap priorities to improve the timely detection, management and care of people affected by pancreatic cancer.	5 early implementation Roadmap priorities funded by the Department of Health and Aged Care delivered. Achieved
Year	Performance Measure	Planned Performance Results
Budget Year 2025–26	N/A	N/A
Forward Estimates 2026–29	N/A	N/A

Program 1.1: Improved Cancer Control		
Year	Performance Measure	Expected Performance Results
Current Year 2024–25	<ol style="list-style-type: none"> 1. Work with First Nations leaders to co-design and deliver improved cancer care for First Nations people aligned with the priorities of the Australian Cancer Plan. 2. Improving First Nations Cancer Outcomes: Lead delivery of activities to ensure mainstream health services are culturally safe and accessible: <ul style="list-style-type: none"> - Partnerships for Culturally Safe Cancer Care grant program to improve cultural safety in cancer services - First Nations Cancer Scholarships to increase Aboriginal and Torres Strait Islander participation in research, health and public policy - Partnerships for Cancer Research grants program to build the capacity of the Indigenous cancer research sector. 	<ol style="list-style-type: none"> 1. First Nations cancer control initiatives led and co-designed by First Nations partners that align with the priorities of the Australian Cancer Plan and complement the strategic objectives of the Aboriginal and Torres Strait Islander Cancer Plan. 2. Improving First Nations cancer Outcomes: Award and support delivery of: <ul style="list-style-type: none"> - <i>Partnerships for Culturally Safe Cancer Care grants</i> - <i>First Nations Cancer Scholarships</i> - <i>Partnerships for Cancer Research grants.</i> <p>On track</p>
Year	Performance Measure	Planned Performance Results
Budget Year 2025–26	<ol style="list-style-type: none"> 1. As per 2024–25 2. As per 2024–25. 	<ol style="list-style-type: none"> 1. As per 2024–25 2. Deliver and commence ongoing evaluation for each initiative: <ul style="list-style-type: none"> - <i>Partnerships for Culturally Safe Cancer Care grants</i> - <i>First Nations Cancer Scholarships</i> - <i>Partnerships for Cancer Research grants.</i>
Forward Estimates 2026–29	<ol style="list-style-type: none"> 1. As per 2025–26 2. As per 2025–26. 	<ol style="list-style-type: none"> 1. As per 2025–26 2. As per 2025–26.

Program 1.1: Improved Cancer Control		
Year	Performance Measure	Expected Performance Results
Current Year 2024–25	Provide evidence-based cancer information to cancer consumers, health professionals and the community.	Up to date evidence-based cancer information was made available on the Cancer Australia website. ≥5 cancer information topics reviewed and updated. On track
Year	Performance Measure	Planned Performance Results
Budget Year 2025–26	As per 2024–25.	Up to date evidence-based cancer information available on the Cancer Australia website. ≥5 cancer information topics are reviewed and updated.
Forward Estimates 2026–29	As per 2025–26.	As per 2025–26.

Program 1.1: Improved Cancer Control		
Year	Performance Measure	Expected Performance Results
Current Year 2024–25	Analyse, interpret and translate evidence to inform best practice cancer care.	Translated research into evidence-based information to assist and inform cancer care policy. On track
Year	Performance Measure	Planned Performance Results
Budget Year 2025–26	As per 2024–25.	Translate research into evidence-based information to assist and inform cancer care policy.
Forward Estimates 2026–29	As per 2025–26.	As per 2025–26.

Program 1.1: Improved Cancer Control		
Year	Performance Measure	Expected Performance Results
Current Year 2024–25	Consult with sector on future priority driven research investment.	Consulted with stakeholders on future priority-driven research investment. Agreed strategic direction for future priority-driven research investment. Achieved
Year	Performance Measure	Planned Performance Results
Budget Year 2025–26	Implement future priority-driven research investment.	Delivery of first grant round of future priority-driven research investment.
Forward Estimates 2026–29	Implement and administer priority-driven research investment annually.	Deliver at least one annual grant round to fund priority-driven research investment.

Program 1.1: Improved Cancer Control		
Year	Performance Measure	Expected Performance Results
Current Year 2024–25	Provide high quality cancer data to inform national cancer control.	Maintained published data analyses and insights on the National Cancer Control Indicators website. On track
Year	Performance Measure	Planned Performance Results
Budget Year 2025–26	As per 2024–25.	Maintain published data analyses and insights on the National Cancer Control Indicators website.
Forward Estimates 2026–29	As per 2025–26.	As per 2025–26.
Material changes to Program 1.1 resulting from 2025–26 Budget Measures: Nil		

Section 3: Budgeted financial statements

Section 3 presents budgeted financial statements which provide a comprehensive snapshot of entity finances for the 2025–26 Budget year, including the impact of budget measures and resourcing on financial statements.

3.1 Budgeted financial statements

3.1.1 Differences between entity resourcing and financial statements

This section is not applicable to Cancer Australia.

3.1.2 Explanatory notes and analysis of budgeted financial statements

Departmental Resources

Comprehensive Income Statement

This statement details budgeted financial results for Cancer Australia in 2025–26.

Cancer Australia's Comprehensive Income Statement depicts a break-even result, net of non-appropriated expenses, depreciation and amortisation expenses, depreciation and amortisation expenses for Right-of-Use asset and lease principal repayments, for the 2025–26 Budget and forward years.

Balance Sheet

Assets and liabilities, excluding Land and Buildings and lease liabilities, are anticipated to remain relatively stable across the forward years. There is an anticipated decrease in Land and Buildings and lease liabilities over the forward estimates.

Cash Flow

Cash flows are consistent with income, expenses and asset movements.

Administered Resources

Administered funding for Cancer Australia programs will continue in 2025–26. The level of administered funding across forward years represents Government expenditure on programs delivered to all Australians through Cancer Australia.

3.2. Budgeted financial statements tables

Table 3.1: Comprehensive income statement (showing net cost of services) for the period ended 30 June

	2024–25 Estimated actual \$'000	2025–26 Budget \$'000	2026–27 Forward estimate \$'000	2027–28 Forward estimate \$'000	2028–29 Forward estimate \$'000
EXPENSES					
Employee benefits	11,736	11,077	11,404	10,669	11,218
Supplier expenses	3,079	2,355	1,882	1,582	1,398
Grants expenses	1,548	1,584	1,618	-	-
Depreciation and amortisation	946	995	1,018	454	259
Interest on RoU	24	17	8	-	-
Other expenses	4	4	4	-	-
Total expenses	17,337	16,032	15,934	12,705	12,875
LESS:					
OWN-SOURCE INCOME					
Revenue					
Other revenue	3,083	2,512	2,067	-	-
Total revenue	3,083	2,512	2,067	-	-
Gains					
Other	72	73	74	70	70
Total gains	72	73	74	70	70
Total own-source income	3,155	2,585	2,141	70	70
Net cost of (contribution by) services	14,182	13,447	13,793	12,635	12,805
Revenue from Government	14,109	13,371	13,742	12,422	12,546
Surplus (deficit)	(73)	(76)	(51)	(213)	(259)
Surplus (deficit) attributable to the Australian Government	(73)	(76)	(51)	(213)	(259)
OTHER COMPREHENSIVE INCOME					
Changes in asset revaluation reserves	-	-	-	-	-
Total other comprehensive income	-	-	-	-	-
Total comprehensive income (loss) attributable to the Australian Government	(73)	(76)	(51)	(213)	(259)

Table 3.1: Comprehensive income statement (showing net cost of services) for the period ended 30 June (continued)

Note: Impact of net cash appropriation arrangements

	2024–25 Estimated actual \$'000	2025–26 Budget \$'000	2026–27 Forward estimate \$'000	2027–28 Forward estimate \$'000	2028–29 Forward estimate \$'000
Total comprehensive income (loss) attributable to the Australian Government	(73)	(76)	(51)	(213)	(259)
plus: non-appropriated expenses depreciation/amortisation expenses	210	259	248	258	259
plus: depreciation/amortisation expenses for RoU assets	736	736	770	196	-
less: lease principal repayments	(873)	(919)	(967)	(241)	-
Total comprehensive income (loss) attributable to the agency	-	-	-	-	-

Prepared on Australian Accounting Standards basis.

RoU = Right-of-Use asset

Table 3.2: Budgeted departmental balance sheet (as at 30 June)

	2024–25 Estimated actual \$'000	2025–26 Budget \$'000	2026–27 Forward estimate \$'000	2027–28 Forward estimate \$'000	2028–29 Forward estimate \$'000
ASSETS					
Financial assets					
Cash and cash equivalents	167	167	167	167	167
Receivables	3,260	3,063	3,058	3,052	2,852
Total financial assets	3,427	3,230	3,225	3,219	3,019
Non-financial assets					
Property, plant and equipment	114	240	152	89	200
Land and buildings	2,230	1,393	556	258	156
Intangibles	14	12	10	10	30
Other	182	182	182	182	182
Total non-financial assets	2,540	1,827	900	539	568
Total assets	5,967	5,057	4,125	3,758	3,587
LIABILITIES					
Payables					
Suppliers	432	428	424	424	424
Other payables	15	15	15	15	15
Total payables	447	443	439	439	439
Interest bearing liabilities					
Leases	2,127	1,208	241	-	-
Total interest bearing liabilities	2,127	1,208	241	-	-
Provisions					
Employees	2,651	2,651	2,651	2,651	2,651
Other provisions	277	281	285	285	285
Total provisions	2,928	2,932	2,936	2,936	2,936
Total liabilities	5,502	4,583	3,616	3,375	3,375
Net assets	465	474	509	383	212
EQUITY					
Contributed equity	1,810	1,895	1,981	2,068	2,156
Reserves	103	103	103	103	103
Retained surpluses or (accumulated deficits)	(1,448)	(1,524)	(1,575)	(1,788)	(2,047)
Total equity	465	474	509	383	212

Prepared on Australian Accounting Standards basis.

Table 3.3: Departmental statement of changes in equity – summary of movement (Budget year 2025–26)

	Retained earnings	Asset revaluation reserve	Contributed equity/ capital	Total equity
	\$'000	\$'000	\$'000	\$'000
Opening balance as at 1 July 2025				
Balance carried forward from previous period	(1,448)	103	1,810	465
Surplus (deficit) for the period	(76)	-	-	(76)
Capital budget - Bill 1 (DCB)	-	-	85	85
Estimated closing balance as at 30 June 2026	(1,524)	103	1,895	474

Prepared on Australian Accounting Standards basis.

DCB = Departmental Capital Budget

Table 3.4: Budgeted departmental statement of cash flows (for the period ended 30 June)

	2024–25 Estimated actual \$'000	2025–26 Budget \$'000	2026–27 Forward estimate \$'000	2027–28 Forward estimate \$'000	2028–29 Forward estimate \$'000
OPERATING ACTIVITIES					
Cash received					
Appropriations	14,117	13,568	13,747	12,428	12,746
Sale of goods and rendering of services	3,083	2,512	2,067	-	-
Net GST received	186	186	186	186	186
Other cash received	-	-	-	-	-
Total cash received	17,386	16,266	16,000	12,614	12,932
Cash used					
Employees	11,736	11,077	11,404	10,669	11,218
Suppliers	3,011	2,286	1,812	1,512	1,328
Interest payments on lease liability	24	17	8	-	-
Grants	1,548	1,584	1,618	-	-
Net GST paid	186	186	186	186	186
Section 74 receipts transferred to the OPA	-	-	-	-	-
Total cash used	16,505	15,150	15,028	12,367	12,732
Net cash from (or used by) operating activities	881	1,116	972	247	200
INVESTING ACTIVITIES					
Cash used					
Purchase of property, plant and equipment and intangibles	93	282	91	93	288
Total cash used	93	282	91	93	288
Net cash from (or used by) investing activities	(93)	(282)	(91)	(93)	(288)
FINANCING ACTIVITIES					
Cash received					
Capital budget - Bill 1 (DCB)	85	85	86	87	88
Total cash received	85	85	86	87	88
Cash used					
Lease principal repayments	873	919	967	241	-
Total cash used	873	919	967	241	-
Net cash from (or used by) financing activities	(788)	(834)	(881)	(154)	88
Net increase (or decrease) in cash held	-	-	-	-	-
Cash and cash equivalents at the beginning of the reporting period	167	167	167	167	167
Cash and cash equivalents at the end of the reporting period	167	167	167	167	167

Prepared on Australian Accounting Standards basis.

DCB = Departmental Capital Budget
OPA = Official Public Account

Table 3.5: Departmental capital budget statement (for the period ended 30 June)

	2024–25 Estimated actual \$'000	2025–26 Budget \$'000	2026–27 Forward estimate \$'000	2027–28 Forward estimate \$'000	2028–29 Forward estimate \$'000
CAPITAL APPROPRIATIONS					
Capital budget - Bill 1 (DCB)	85	85	86	87	88
Total capital appropriations	85	85	86	87	88
Total new capital appropriations represented by:					
Purchase of non-financial assets	85	85	86	87	88
Total represented by	85	85	86	87	88
PURCHASE OF NON-FINANCIAL ASSETS					
Funded by capital appropriation - DCB ^(a)	85	85	86	87	88
Funded internally from departmental resources	8	197	5	6	200
Total acquisitions of non-financial assets	93	282	91	93	288
RECONCILIATION OF CASH USED TO ACQUIRE ASSETS TO ASSET MOVEMENT TABLE					
Total purchases	93	282	91	93	288
Total cash used to acquire assets	93	282	91	93	288

Prepared on Australian Accounting Standards basis.

DCB = Departmental Capital Budget

^(a) Does not include annual finance lease costs. Includes purchases from current and previous years' DCB.

Table 3.6: Statement of departmental asset movements (Budget year 2025–26)

	Buildings	Property, plant and equipment	Intangibles	Total
	\$'000	\$'000	\$'000	\$'000
As at 1 July 2025				
Gross book value	1,219	2,128	1,346	4,693
Gross book value - RoU	4,874	-	-	4,874
Accumulated depreciation/amortisation and impairment	(691)	(2,014)	(1,332)	(4,037)
Accumulated depreciation/amortisation and impairment - RoU	(3,172)	-	-	(3,172)
Opening net book balance	2,230	114	14	2,358
CAPITAL ASSET ADDITIONS				
Estimated expenditure on new or replacement assets				
Funded by capital appropriation - - DCB ^(a)	-	85	-	85
Funded internally from departmental resources	-	189	8	197
By purchase - RoU	-	-	-	-
Total additions	-	274	8	282
Other movements				
Depreciation/amortisation expense	(101)	(148)	(10)	(259)
Depreciation/amortisation expense - RoU	(736)	-	-	(736)
Total other movements	(837)	(148)	(10)	(995)
As at 30 June 2026				
Gross book value	1,219	2,402	1,354	4,975
Gross book value - RoU	4,874	-	-	4,874
Accumulated depreciation amortisation and impairment	(792)	(2,162)	(1,342)	(4,296)
Accumulated depreciation/amortisation and impairment - RoU	(3,908)	-	-	(3,908)
Closing net book balance	1,393	240	12	1,645

Prepared on Australian Accounting Standards basis.

DCB = Departmental Capital Budget
RoU = Right-of-Use asset

^(a) Does not include annual finance lease costs. Includes purchases from current and previous years' DCB.

Table 3.7: Schedule of budgeted income and expenses administered on behalf of Government (for the period ended 30 June)

	2024–25 Estimated actual \$'000	2025–26 Budget \$'000	2026–27 Forward estimate \$'000	2027–28 Forward estimate \$'000	2028–29 Forward estimate \$'000
EXPENSES ADMINISTERED ON BEHALF OF GOVERNMENT					
Grants	21,800	23,175	23,055	15,680	15,128
Suppliers	12,562	10,024	10,333	6,928	7,196
Total expenses administered on behalf of Government	34,362	33,199	33,388	22,608	22,324
INCOME ADMINISTERED ON BEHALF OF GOVERNMENT					
Revenue					
Non-taxation					
Other non-tax revenue	-	-	-	-	-
Total non-taxation revenue	-	-	-	-	-
Total revenues administered on behalf of Government	-	-	-	-	-
Total income administered on behalf of Government	-	-	-	-	-

Prepared on Australian Accounting Standards basis.

Table 3.8: Schedule of budgeted assets and liabilities administered on behalf of Government (as at 30 June)

	2024–25 Estimated actual \$'000	2025–26 Budget \$'000	2026–27 Forward estimate \$'000	2027–28 Forward estimate \$'000	2028–29 Forward estimate \$'000
ASSETS ADMINISTERED ON BEHALF OF GOVERNMENT					
Financial assets					
Cash and cash equivalents	30	30	30	30	30
Receivables	840	840	840	840	840
Total financial assets	870	870	870	870	870
Non financial assets					
Prepayments	112	112	112	112	112
Total financial assets	112	112	112	112	112
Total assets administered on behalf of Government	982	982	982	982	982
LIABILITIES ADMINISTERED ON BEHALF OF GOVERNMENT					
Payables					
Suppliers	561	561	561	561	561
Grants	587	587	587	587	587
Total payables	1,148	1,148	1,148	1,148	1,148
Total liabilities administered on behalf of Government	1,148	1,148	1,148	1,148	1,148

Prepared on Australian Accounting Standards basis.

Table 3.9: Schedule of budgeted administered cash flows (for the period ended 30 June)

	2024–25 Estimated actual \$'000	2025–26 Budget \$'000	2026–27 Forward estimate \$'000	2027–28 Forward estimate \$'000	2028–29 Forward estimate \$'000
OPERATING ACTIVITIES					
Cash received					
Net GST received	624	624	624	624	624
Other	-	-	-	-	-
Total cash received	624	624	624	624	624
Cash used					
Grant payments	21,892	23,267	23,147	15,772	15,220
Suppliers	13,094	10,556	10,865	7,460	7,728
Total cash used	34,986	33,823	34,012	23,232	22,948
Net cash from (or used by) operating activities	(34,362)	(33,199)	(33,388)	(22,608)	(22,324)
Net increase (or decrease) in cash held	(34,362)	(33,199)	(33,388)	(22,608)	(22,324)
Cash at beginning of reporting period	30	30	30	30	30
Cash from the OPA for:					
- appropriations	34,362	33,199	33,388	22,608	22,324
- GST	624	624	624	624	624
Cash to the OPA					
- return of GST	(624)	(624)	(624)	(624)	(624)
- other	-	-	-	-	-
Cash at end of reporting period	30	30	30	30	30

Prepared on Australian Accounting Standards basis.

OPA = Official Public Account